Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

702
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
702
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

832
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
832
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

574
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
574
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

497
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
497
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

451
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
451
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Part I: Speech Characteristics of the Disorder.

Language, speech, and hearing services in schools·2000
Same author

Part II: The Nature and Causes of DAS.

Language, speech, and hearing services in schools·2000
Same author

Part III: Other Problems Often Associated With the Disorder.

Language, speech, and hearing services in schools·2000
See all related articles

Related Experiment Video

Updated: Mar 13, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.9K

Part IV: Treatment of DAS.

Penelope K Hall1

  • 1The University of Iowa, Iowa City.

Language, Speech, and Hearing Services in Schools
|April 1, 2000
PubMed
Summary

This letter discusses treatment options for children with developmental apraxia of speech (DAS). It provides resources for parents seeking further information on managing this speech disorder.

Area of Science:

  • Speech-Language Pathology
  • Child Development
  • Pediatric Neurology

Background:

  • Developmental apraxia of speech (DAS) is a complex motor speech disorder affecting speech production in children.
  • Previous communications detailed DAS characteristics, etiology, and co-occurring conditions.
  • This letter focuses specifically on therapeutic interventions for DAS.

Purpose of the Study:

  • To outline treatment approaches for developmental apraxia of speech (DAS).
  • To provide parents with accessible information on managing DAS.
  • To offer resources for further in-depth review of DAS treatment.

Main Methods:

  • This letter synthesizes information on established and emerging treatment strategies for DAS.
  • It includes a curated appendix of relevant publications for continued learning.

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K
Accessing the Subdural Space of the Rodent Spinal Cord for Treatment Delivery
07:54

Accessing the Subdural Space of the Rodent Spinal Cord for Treatment Delivery

Published on: August 8, 2025

633

Related Experiment Videos

Last Updated: Mar 13, 2026

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
09:16

A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration

Published on: January 22, 2016

15.9K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K
Accessing the Subdural Space of the Rodent Spinal Cord for Treatment Delivery
07:54

Accessing the Subdural Space of the Rodent Spinal Cord for Treatment Delivery

Published on: August 8, 2025

633
  • The content is framed as a direct communication to parents of children with DAS.

    • Main Results:

    • Treatment for DAS typically involves intensive, individualized speech therapy.
    • Multidisciplinary approaches may be beneficial, addressing co-occurring challenges.
    • Parental involvement and understanding are crucial for successful intervention.

    Conclusions:

    • Effective management of DAS requires tailored therapeutic interventions.
    • Access to comprehensive resources supports informed decision-making for parents.
    • Ongoing research continues to refine treatment protocols for pediatric speech disorders.